INCY Stock Summary and Trading Ideas (Incyte | NASDAQ:INCY)

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

What symbol and exchange does Incyte shares trade?

Incyte trades on the NASDAQ stock market under the symbol INCY.

What is Incyte stock price doing today?

As of March 27, 2026, INCY stock price declined to $90.30 with 1,421,435 million shares trading.

What is Incyte's Beta?

INCY has a beta of 0.36, meaning it tends to be less sensitive to market movements. INCY has a correlation of 0.03 to the broad based SPY ETF.

How much is Incyte worth?

INCY has a market cap of $17.97 billion. This is considered a Large Cap stock.

How much money does Incyte make?

Last quarter Incyte reported $2 billion in Revenue and $1.80 earnings per share. This beat revenue expectation by $154 million and missed earnings estimates by -$.03.

What is the highest and lowest price Incyte traded in the last 3 year period?

In the last 3 years, INCY traded as high as $112.29 and as low as $50.27.

What are the top ETFs holding Incyte?

The top ETF exchange traded funds that INCY belongs to (by Net Assets): VTI, VOO, VB, VBK, IVV.

Is Incyte (INCY) a good investment?

INCY has outperformed the market in the last year with a price return of +47.4% while the SPY ETF gained +12.8%. However, in the short term, INCY had mixed performance relative to the market. It has underperformed in the last 3 months, returning -9.8% vs -7.9% return in SPY. But in the last 2 weeks, INCY shares have fared better than the market returning -1.9% compared to SPY -4.5%.

What are the support and resistance levels for Incyte (INCY)?

INCY support price is $90.66 and resistance is $93.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INCY shares will trade within this expected range on the day.